Compare BioNano Genomics Inc (BNGO) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while State Street SPDR S&P Homebuilders ETF trades at $108.96. The key difference: State Street SPDR S&P Homebuilders ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | XHB | |
|---|---|---|
Market Cap | $13.20M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $4.92 | $121.36 |
52-Week Low | $1.09 | $94.86 |
Enterprise Value | $15.81M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
XHB trades at $107.07, down 1.42% amid bearish technical signals, with support at $104 and resistance at $110. The ETF faces mixed housing data with declining existing home sales but potential tailwinds from new housing legislation. Key indicators show oversold short-term RSI but strong bearish momentum from ADX.
Outlook is cautious due to high mortgage rates and record home prices pressuring demand, though legislative support for homebuilders offers upside. Risks include interest rate sensitivity and economic slowdowns. Analyst sentiment is neutral with focus on housing market recovery timing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
